We are live on !
Find out more
HighMark Wealth Management Portfolio holdings
AUM
$299M
Turnover
13.67%
1-Year Est. Return
53.01%
This Fund
S&P 500
This Quarter Est. Return
+21.77%
1 Year Est. Return
+53.01%
3 Year Est. Return
+109.68%
5 Year Est. Return
+113.63%
10 Year Est. Return
–
AUM
$299M
AUM Growth
+$52.9M
(+22%)
Cap. Flow
+$8.26M
Cap. Flow % of AUM
Cap. Flow %
2.77%
Top 10 Holdings %
Top 10 Hldgs %
65.82%
Holding
600
New
46
Increased
156
Reduced
94
Closed
36
Avg Time Held
Equity + Options
3.4
years
Top 10 Avg Time Held
Equity + Options
2.7
years
Top 20 Avg Time Held
Equity + Options
2.3
years
Avg Time Held Equity only
3.4
years
Top 10 Avg Time Held Equity only
2.7
years
Top 20 Avg Time Held Equity only
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Health Care Index ETF
FHLC
|
+$18.3M |
| 2 |
SI-BONE Inc
SIBN
|
+$3.79M |
| 3 |
Duos Technologies
DUOT
|
+$2.91M |
| 4 |
Apogee Therapeutics
APGE
|
+$2.91M |
| 5 |
Neuropace
NPCE
|
+$1.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$9.41M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$5.14M |
| 3 |
AnaptysBio
ANAB
|
+$3.29M |
| 4 |
iShares MSCI EAFE Value ETF
EFV
|
+$1.64M |
| 5 |
Piper Sandler
PIPR
|
+$1.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 64.9% |
| 2 | Healthcare | 21.84% |
| 3 | Technology | 4.77% |
| 4 | Financials | 3.58% |
| 5 | Industrials | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
201
State Street Health Care Select Sector SPDR ETF
XLV
$46.6B
| $35.4K | 0.01% |
223
+1
| +0.5% | +$149 |
2019 Q4
26 quarters
|
|
202
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $35K | 0.01% |
221
| – | – |
2021 Q3
19 quarters
|
|
203
Amplify Alternative Harvest ETF
MJ
$95.4M
| $34.6K | 0.01% |
1,345
| – | – |
2019 Q4
26 quarters
|
|
204
Grayscale Ethereum Staking Mini ETF Shares
ETH
$2.01B
| $34K | 0.01% |
2,265
+400
| +21% | +$7.81K |
2025 Q3
3 quarters
|
|
205
Synaptics
SYNA
$4.66B
| $33.4K | 0.01% |
269
| – | – |
2019 Q4
26 quarters
|
|
206
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
$67.4B
| $33.1K | 0.01% |
+400
| New | +$33.1K |
2026 Q2
0 quarters
|
|
207
GE Vernova
GEV
$217B
| $33K | 0.01% |
28
-1
| -3% | -$1.02K |
2024 Q2
8 quarters
|
|
208
DELISTED
Warner Bros
WBD
| $32.9K | 0.01% |
1,235
+668
| +118% | +$18.1K |
2022 Q2
16 quarters
|
|
209
Verisk Analytics
VRSK
$25.5B
| $32.7K | 0.01% |
182
| – | – |
2023 Q1
13 quarters
|
|
210
Rigetti Computing
RGTI
$3.85B
| $32.4K | 0.01% |
1,678
+20
| +1% | +$387 |
2024 Q4
6 quarters
|
|
211
Oracle
ORCL
$382B
| $31.9K | 0.01% |
218
+41
| +23% | +$7.43K |
2025 Q2
4 quarters
|
|
212
DraftKings
DKNG
$10.4B
| $31.3K | 0.01% |
1,240
| – | – |
2020 Q3
23 quarters
|
|
213
Otter Tail
OTTR
$3.8B
| $30.6K | 0.01% |
340
+2
| +0.6% | +$177 |
2025 Q2
4 quarters
|
|
214
ASML
ASML
$606B
| $29.9K | 0.01% |
15
+6
| +67% | +$9.6K |
2019 Q4
26 quarters
|
|
215
General Mills
GIS
$18.4B
| $29.3K | 0.01% |
841
+14
| +2% | +$483 |
2019 Q4
26 quarters
|
|
216
Steris
STE
$22.6B
| $29.1K | 0.01% |
138
| – | – |
2019 Q4
26 quarters
|
|
217
iShares MSCI Emerging Markets Min Vol Factor ETF
EEMV
$3.44B
| $28.8K | 0.01% |
383
+100
| +35% | +$7.2K |
2020 Q3
23 quarters
|
|
218
Organogenesis Holdings
ORGO
$128M
| $28.7K | 0.01% |
11,829
-291,200
| -96% | -$712K |
2025 Q2
4 quarters
|
|
219
Comcast
CMCSA
$80.5B
| $28.4K | 0.01% |
1,158
-602
| -34% | -$15.5K |
2019 Q4
26 quarters
|
|
220
Vanguard Morningstar Growth ETF
VUG
$224B
| $28.3K | 0.01% |
328
-2
| -0.6% | -$168 |
2024 Q2
8 quarters
|
|
221
Protolabs
PRLB
$2.05B
| $28.1K | 0.01% |
345
| – | – |
2021 Q4
18 quarters
|
|
222
iShares Russell Mid-Cap Growth ETF
IWP
$18.7B
| $28K | 0.01% |
191
| – | – |
2023 Q3
11 quarters
|
|
223
iShares MSCI Global Silver and Metals Miners ETF
SLVP
$772M
| $27.9K | 0.01% |
905
+4
| +0.4% | +$143 |
2025 Q4
2 quarters
|
|
224
Merck
MRK
$358B
| $27.9K | 0.01% |
217
+103
| +90% | +$12.1K |
2022 Q1
17 quarters
|
|
225
Nike
NKE
$55.4B
| $27.6K | 0.01% |
673
+91
| +16% | +$4K |
2019 Q4
26 quarters
|
|
Similar funds
HighMark Wealth Management's Q2 2026 Portfolio in Review
As of Q2 2026, HighMark Wealth Management held 600 positions worth $299M, up 22% from $246M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
HighMark Wealth Management's Q2 2026 filing shows 46 new, 156 increased, 94 reduced and 36 closed positions. Its largest new stake was Duos Technologies: 289,884 shares worth $3.48M. The largest sale was Centessa Pharmaceuticals, an estimated $9.41M.
By sector, the portfolio is most concentrated in Miscellaneous at 65% of assets, down from 65% a quarter earlier, followed by Healthcare and Technology.
- HighMark Wealth Management's largest Q2 2026 buy was Duos Technologies: 289,884 shares worth $3.48M.
- HighMark Wealth Management added most to Fidelity MSCI Health Care Index ETF in Q2 2026, an estimated $18.3M increase.
- HighMark Wealth Management's biggest Q2 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $5.14M.
- HighMark Wealth Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $9.41M.
- HighMark Wealth Management's ten largest holdings make up 66% of its $299M portfolio in Q2 2026.
- HighMark Wealth Management opened 46 new positions and closed 36 in Q2 2026.
- HighMark Wealth Management's portfolio value rose 22% quarter-over-quarter to $299M.
Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.